ArticleThe journal of trauma and acute care surgery2026
Role of peptidylarginine deiminase 2 in a murine model of traumatic brain injury.
Article in The journal of trauma and acute care surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
introductionTraumatic brain injury (TBI) is among the leading causes of death and disability worldwide. Studies have linked peptidylarginine deiminases (PADs) with TBI outcomes. However, nonspecific PAD inhibition makes it difficult to decipher the exact role of specific PAD enzymes in neurotrauma. Since both PAD2 and PAD4 have been linked with neurodegeneration, we sought to clearly establish their roles in TBI.
methodsMale mice (11-14 weeks) were subjected to controlled cortical impact TBI (n = 5/group). Experimental groups included wild-type plus TBI (WT-TBI), PAD2 knockout plus TBI (PAD2-KO-TBI), PAD4 knockout plus TBI (PAD4-KO-TBI), and PAD2/4 double knockout plus TBI (PAD2/4-DKO-TBI). Twenty-four hours post-TBI, frozen brain sections were stained (Nissl and immunofluorescence) to determine lesion size and expression of PAD2 and PAD4. We also assessed the impact of PAD2-KO on neurologic severity scores (1-8 days post-TBI) and visuospatial learning using the Morris water maze test (21-30 days post-TBI).
resultsOverall, PAD2-KO-TBI and PAD2/4-DKO-TBI animals displayed significantly smaller brain lesion sizes than WT-TBI (p = 0.005 and 0.005, respectively) and PAD4-KO-TBI (p = 0.005 and 0.004, respectively). However, there was no significant difference in lesion size between the PAD4-KO-TBI and WT-TBI (p = 0.880) groups. Analysis of archived snRNA-seq data and immunofluorescence staining 24 hours post-TBI showed upregulation of PAD2 (primarily in astrocytes) in WT-TBI compared with sham (p = 0.048), whereas PAD4 was undetectable. Overall, PAD2-KO-TBI had a significantly lower neurologic severity score on postinjury days 1 to 6 compared with WT-TBI (all p < 0.05) group. Moreover, Morris water maze test demonstrated that the cumulative cued and noncued spatial learning was worse in WT-TBI compared with PAD2-KO-TBI (p < 0.05) animals.
conclusionOur results suggest that PAD2, but not PAD4, blockade can improve outcomes following TBI, which justifies its exploration as a potential target for novel neuroprotective therapies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.